In 2026, pharma companies must translate AI, innovative pipelines, and smart manufacturing into tangible competitive advantage. With $176 billion in revenues exposed to the patent cliff, major reshoring investments underway, and mounting EU regulatory pressures, the challenge is no longer discovering more—it is industrializing better.

Only 8% of European countries have developed an AI strategy specifically tailored to healthcare, and just 6% have introduced legal requirements addressing generative AI in clinical settings. Regulatory uncertainty is cited by 86% of member states as the primary barrier to adoption. For the pharmaceutical industry, the challenge is not innovation per se, but the ability to translate it into compliant, interoperable, and economically sustainable solutions within a regulatory framework that is still taking shape.

A novelty in the world of biomaterials

Genenta announces Long-Term follow-up observations in brain tumor (GBM) study with emerging survival signals

The October issue of MakingPharmaIndustry accompanies CPhI Frankfurt 2025, showcasing how research, technology, and industry are reshaping the future of Pharma. From advanced therapies to sustainable manufacturing, from AI to regulatory quality, the tabloid explores the people, ideas, and innovations driving a new era of global health.

In the March multimedia magazine, we explore the impact of artificial intelligence and cybersecurity regulations in the pharmaceutical industry. As artificial intelligence reshapes drug development,...